Compare antipsychotic medicines for Parkinson or Lewy body psychosis
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study compares two medicines—quetiapine and pimavanserin—in people with psychosis caused by Parkinson’s disease or Lewy body dementia, looking at how they work over time. You might join if you are starting an antipsychotic for the first time and your clinician can safely manage either option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a patient seen in the UT Health San Antonio neurology clinic
- You have psychosis caused by Parkinson’s disease or Lewy body dementia
- You are starting an antipsychotic medicine (not already taking one now)
- Your doctor believes either quetiapine or pimavanserin could be reasonable for you
- Your doctor is willing and able to prescribe and monitor both quetiapine and pimavanserin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two drugs, pimavanserin and quetiapine, to see which works better for hallucinations or delusions caused by Parkinson's disease. The goal is to help patients manage these symptoms more effectively.
This study looks at how brain changes affect attention and thinking in people with Lewy body dementia. It includes brain scans, an EEG, and a medication option to see if it helps with symptoms.
This early-stage study tests whether the blood-pressure medicine terazosin can improve thinking and behavior in people with dementia with Lewy bodies. If you qualify, you would stay on your current dementia medicines for at least a few weeks so researchers can better see terazosin’s effect.
This study uses a special PET brain scan tracer to better understand serotonin receptor activity in people with certain neurodegenerative conditions, especially when they develop hallucinations or delusions. The results may help researchers improve how these brain changes are measured and tracked over time.
This trial tests if pimavanserin can reduce impulse control disorders like gambling, shopping, hypersexuality, or overeating in people with Parkinson's disease. It aims to help those whose symptoms are moderate but not too severe.
This Phase 2 study tests whether AGB101 (levetiracetam) can reduce hallucinations, delusions, or related symptoms in people with Parkinson’s disease psychosis, while checking safety. You and a study partner will help with dosing and regular check-ins, including MRI scans.
Hear when a new Dementia With Lewy Bodies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.